Alexion Pharmaceuticals, Inc.
This is a Phase 3b, open-label, single-arm, multicenter study to evaluate the efficacy and safety of eculizumab in participants with atypical hemolytic uremic syndrome (aHUS) in China.
Atypical Hemolytic Uremic
Eculizumab
Phase 3
This is a Phase 3b, open-label, single-arm, multicenter study to evaluate the efficacy and safety of eculizumab in participants with aHUS in China. The study will be conducted in participants of any age who weigh ≥ 5 kg and who previously have not been treated with complement inhibitors. The study consists of an up to 7-day Screening Period and a 26-week Treatment Period. An 8-week Safety Follow-up Phone Call will be required only for participants who discontinue eculizumab treatment during the study or for participants who will not receive continued access to eculizumab after completing study treatment. Approximately 25 eligible participants in China will be enrolled.}}
Study Type : | Interventional |
Estimated Enrollment : | 25 participants |
Masking : | None (Open Label) |
Primary Purpose : | Treatment |
Official Title : | Prospective, Single-Arm, Multicenter Study to Evaluate the Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Eculizumab in Complement Inhibitor Treatment-Naïve Pediatric and Adult Participants With Atypical Hemolytic Uremic Syndrome (aHUS) in China |
Actual Study Start Date : | July 14, 2023 |
Estimated Primary Completion Date : | March 31, 2026 |
Estimated Study Completion Date : | March 31, 2026 |
Arm | Intervention/treatment |
---|---|
Experimental: Eculizumab Participants will receive Eculizumab in a single dose vial. |
Drug: Eculizumab |
Ages Eligible for Study: | |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.
Recruiting
Research Site
Beijing, China, 100034
Recruiting
Research Site
Beijing, China, 100045
Recruiting
Research Site
Changsha, China, 410007
Recruiting
Research Site
Chengdu, China, 610041
Recruiting
Research Site
Guangzhou, China, 510062
Recruiting
Research Site
Nanchang, China, 330006
Recruiting
Research Site
Nanjing, China, 210002
Recruiting
Research Site
Qingdao, China, 110016
Recruiting
Research Site
Shenzhen, China, 518036
Recruiting
Research Site
Suzhou, China, 215002
Recruiting
Research Site
Taiyuan, China, 030012
Recruiting
Research Site
Wuhan, China, 430030
Recruiting
Research Site
Y Antai, China, 264000
Recruiting
Research Site
Zhengzhou, China, 450018
Recruiting
Research Site
Zhengzhou, China, 450052